Organon & Co. (NYSE:OGN) Shares Acquired by Principle Wealth Partners LLC

Principle Wealth Partners LLC lifted its position in shares of Organon & Co. (NYSE:OGN) by 15.3% in the 4th quarter, according to its most recent filing with the Securities & Exchange Commission. The fund owned 24,571 shares of the company’s stock after buying an additional 3,259 shares during the quarter. Principle Wealth Partners LLC’s holdings in Organon & Co. were worth $367,000 at the end of the most recent quarter.

Several other hedge funds and other institutional investors have also made changes to their positions in the company. Wilmington Savings Fund Society FSB increased its position in Organon & Co. by 12.9% during the 4th quarter. Wilmington Savings Fund Society FSB now owns 10,910 shares of the company’s stock worth $163,000 after purchasing an additional 1,248 shares in the last quarter. Kingsview Wealth Management LLC purchased a new stake in Organon & Co. during the 4th quarter worth about $542,000. Measured Wealth Private Client Group LLC increased its position in Organon & Co. by 68.4% during the 4th quarter. Measured Wealth Private Client Group LLC now owns 35,586 shares of the company’s stock worth $531,000 after purchasing an additional 14,449 shares in the last quarter. Bleakley Financial Group LLC increased its position in Organon & Co. by 302.9% during the 4th quarter. Bleakley Financial Group LLC now owns 48,372 shares of the company’s stock worth $722,000 after purchasing an additional 36,367 shares in the last quarter. Finally, Private Management Group Inc. increased its position in Organon & Co. by 11.9% during the 4th quarter. Private Management Group Inc. now owns 2,119,288 shares of the company’s stock worth $31,620,000 after purchasing an additional 225,420 shares in the last quarter. Institutional investors and hedge funds own 77.43% of the company’s stock.

Organon & Co. Stock Down 0.5 %

OGN opened at $14.96 on Wednesday. The company has a debt-to-equity ratio of 17.73, a current ratio of 1.70 and a quick ratio of 1.21. The stock has a market capitalization of $3.85 billion, a price-to-earnings ratio of 2.97, a price-to-earnings-growth ratio of 0.83 and a beta of 0.76. The business has a 50-day moving average of $15.34 and a two-hundred day moving average of $17.56. Organon & Co. has a 12 month low of $13.87 and a 12 month high of $23.10.

Analyst Upgrades and Downgrades

Separately, TD Cowen upgraded Organon & Co. to a “hold” rating in a research report on Wednesday, January 15th. One equities research analyst has rated the stock with a sell rating, two have assigned a hold rating, one has given a buy rating and one has issued a strong buy rating to the stock. Based on data from MarketBeat, the stock has an average rating of “Hold” and an average price target of $21.33.

Organon & Co. Profile

Organon & Co is a science based global pharmaceutical company, which develops and delivers innovative health solutions through a portfolio of prescription therapies within women’s health, biosimilars and established brands. The company was founded on March 11, 2020, and is headquartered in Jersey City, NJ.